NCT05208567 London Valvular Heart Disease and Reduced Ejection Fraction Detection in a Multi-ethnic Community Using Cardiac Ultrasound
| NCT ID | NCT05208567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Heart Valve Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-03-14 |
| Primary Completion | 2026-08-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-03-14 with a primary completion date of 2026-08-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart Valve Disease and Heart failure contribute to 25% of hospital emergency admissions while heart failure alone has become one of the most common causes for hospitalisation in people over the age of 65. The burden of disease is likely to be high in a multi-ethnic community but there is a paucity of data. Management of heart valve disease requires appropriate surveillance and timely surgery. Similarly heart failure management requires treatment with medications aimed at slowing prevention of symptoms and preventing premature death. The NHS long term plan priorities early detection and treatment of valve disease and heart failure in order to reduce the burden on emergency services and improve the health of the population. Diagnosis is made using cardiac ultrasound, however staff with the required skills-set are critically limited in the community. The investigators will train non-expert staff within primary care to perform abbreviated cardiac ultrasound to detect heart valve disease or heart failure. This will be opportunistic scanning to reduce healthcare footfall. All scans will be reviewed by an expert and the investigators will use the anonymised data to develop machine learning tools to begin working with academic partners to develop tools that can improve the reliability of diagnosis from ultrasound. The investigators hope to identify the proportion with the above conditions in a multi-ethnic community and assess the feasibility of developing a program where staff can be trained for community detection, streamlined referrals can be created bridging the gap between primary and secondary care, reducing hospital emergency admissions, while ensuring patients are managed optimally.
Eligibility Criteria
Inclusion Criteria: \- Greater or equal to 65 years old Exclusion Criteria: * Clinical diagnosis of Alzheimer's Disease or Vascular Dementia * Palliative Care patients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05208567 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Heart Valve Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05208567 currently recruiting?
Yes, NCT05208567 is actively recruiting participants. Contact the research team at nabila.laskar@nhs.net for enrollment information.
Where is the NCT05208567 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT05208567 clinical trial?
NCT05208567 is sponsored by Queen Mary University of London. The trial plans to enroll 500 participants.